BFM
SPRY icon

Boothbay Fund Management’s ARS Pharmaceuticals SPRY Stock Holding History

Boothbay Fund Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-204,600
Closed -$2.06M – 2335
2025
Q3 		$2.06M Buy
+204,600
New +$2.94M 0.03% 562

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Boothbay Fund Management's SPRY Position: Q2 2026 in Review

Boothbay Fund Management increased its ARS Pharmaceuticals (SPRY) stake by 539% in Q2 2026, buying an estimated $11.6M and bringing the position to 1,601,504 shares worth $12.8M. The position accounts for 0.17% of the portfolio, ranked #116.

Boothbay Fund Management first reported a position in SPRY in Q4 2022 and has held it in 6 quarters since. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Boothbay Fund Management held 1,601,504 shares of ARS Pharmaceuticals worth $12.8M as of Q2 2026.
  • Boothbay Fund Management bought 1,350,907 ARS Pharmaceuticals shares in Q2 2026, an estimated $11.6M.
  • ARS Pharmaceuticals made up 0.17% of Boothbay Fund Management's portfolio in Q2 2026, its #116 holding.
  • Boothbay Fund Management first reported a position in ARS Pharmaceuticals in Q4 2022 and has held it in 6 quarters since.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.